Taisho Buys Biofermin In All-Japanese Acquisition
This article was originally published in PharmAsia News
Executive Summary
Japan's Taisho Pharmaceutical has bought a controlling interest in Biofermin Pharmaceutical for $240.2 million. The Taisho purchase amounts to a 54.8 percent stake in Biofermin, which Taisho plans to make a subsidiary. Biofermin has a marketing agreement with Takeda Pharmaceutical, which opposed the Taisho bid, but that contract is to remain in place. The acquiring company plans to develop lactobacillus products, using Biofermin facilities. (Click here for more - may require a subscription